SG Americas Securities LLC Purchases 367,692 Shares of Sarepta Therapeutics, Inc. $SRPT

SG Americas Securities LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 192.1% in the first quarter, HoldingsChannel reports. The fund owned 559,063 shares of the biotechnology company’s stock after acquiring an additional 367,692 shares during the period. SG Americas Securities LLC’s holdings in Sarepta Therapeutics were worth $12,165,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Yousif Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock valued at $541,000 after purchasing an additional 481 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Sarepta Therapeutics by 1.8% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Sarepta Therapeutics by 82.5% during the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 851 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in Sarepta Therapeutics by 3.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 24,620 shares of the biotechnology company’s stock valued at $530,000 after purchasing an additional 896 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SRPT shares. Citigroup lifted their price target on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Mizuho raised their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Wells Fargo & Company lowered their target price on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $24.81.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $16.85 on Friday. The company has a fifty day moving average price of $18.12 and a two-hundred day moving average price of $19.46. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $25.32. The stock has a market cap of $1.78 billion, a P/E ratio of -17.55, a P/E/G ratio of 0.17 and a beta of 0.21. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. Sarepta Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.42) EPS. As a group, equities analysts predict that Sarepta Therapeutics, Inc. will post 3.95 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.